Cite

HARVARD Citation

    Shima, M. et al. (2019). A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 25 (6), pp. 979-987. [Online]. 
  
Back to record